VERAXA Biotech AG (NASDAQ: VRXA) announced that shareholders voted overwhelmingly in favor of all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in support and 72.20% of the company’s outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030, and an increase in the maximum size of the board of directors from five to seven members.
According to the company, the enhanced corporate and financing framework is designed to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities, and continued development of its BiTAC(R) technology platform and oncology pipeline. Management noted that the vote reflects strong shareholder support for VERAXA’s strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
The approval of these governance and financing measures is significant for VERAXA as it seeks to strengthen its position in the competitive oncology therapeutics market. By expanding the board and introducing conditional capital, the company gains the agility to pursue strategic initiatives without the need for repeated shareholder approvals. This could accelerate potential partnerships or acquisitions that may enhance its pipeline or technology platform. The capital band, extending through 2030, provides a long-term financing tool that can be utilized as market conditions allow.
For investors, the high level of shareholder support signals confidence in VERAXA’s direction and management. The company’s focus on antibody-based cancer therapies, particularly its BiTAC platform, positions it in a rapidly growing segment of biotech. The ability to issue shares via warrants and options could also be used to attract and retain talent, further supporting development efforts.
More information about VERAXA and its latest updates is available on its newsroom at http://ibn.fm/VRXA. The full press release detailing the shareholder vote can be accessed at https://ibn.fm/qfL87.
